Literature DB >> 2808746

Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism.

C Hoyo-Vadillo1, G Castañeda-Hernández, J E Herrera, J Vidal-Gárate, A Moreno-Ramos, F Chávez, E Hong.   

Abstract

Nifedipine kinetics after ingestion of 20 mg slow release tablets were studied in 12 young, healthy, Mexican subjects. Plasma levels were determined by a nifedipine-specific HPLC assay. Levels rose after drug administration reaching a maximum concentration of 48.7 +/- 7.3 ng/ml in 2.1 +/- 0.7 h (mean +/- SEM). Concentrations then decayed with a terminal half-life of 16.9 +/- 3.1 hours. AUC was 526 +/- 62 ng h/ml. Five individuals were fast and seven were slow nifedipine metabolizers, according to the AUC criterion proposed by Kleinbloesem and coworkers. Individual AUC/Dose values from this and from other two studies on oral nifedipine kinetics in Mexicans were cumulated and the frequency histogram and probit analyses were performed (N = 30). A bimodal distribution was clearly observed. Fast and slow metabolizers were distinguished as those subjects with AUC/Dose values either lower or higher than 22.5 ng h/ml mg. Unlike European populations, it appears that slow metabolization is more frequent in Mexicans. Data strongly support the hypothesis of the existence of a polymorphism concerning nifedipine disposition kinetics due to genetic basis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808746     DOI: 10.1002/j.1552-4604.1989.tb03425.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  Ethnic differences in the pharmacokinetics of oral nifedipine.

Authors:  C H Ahsan; A G Renwick; B Macklin; V F Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 3.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 5.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 6.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

7.  Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.

Authors:  A Sowunmi; T J Rashid; O O Akinyinka; A G Renwick
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

8.  Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients with Severe Preeclampsia: A Randomized, Single-Blind, Controlled Trial.

Authors:  Gilberto Arias-Hernández; Cruz Vargas-De-León; Claudia C Calzada-Mendoza; María Esther Ocharan-Hernández
Journal:  Int J Hypertens       Date:  2020-07-23       Impact factor: 2.420

Review 9.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

10.  Factors affecting the absolute bioavailability of nifedipine.

Authors:  T J Rashid; U Martin; H Clarke; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.